Transitioning your patients from Flolan® (epoprostenol sodium)1

Transitioning from Flolan to SC Remodulin1,2

Subcutaneous Remodulin has been demonstrated to diminish the rate of clinical deterioration* in patients requiring transition from Flolan.

  • An 8-week, multicenter, randomized (2:1), placebo-controlled, withdrawal trial of 22 patients stable on epoprostenol therapy who were started on SC Remodulin or placebo
  • Time to clinical deterioration* was the primary endpoint of this trial
  • Safety findings were consistent with previous clinical trials of SC Remodulin

*Clinical deterioration was defined as an increase in Flolan dose, hospitalization due to PAH, or death (no patients died during this study).1

Subcutaneous Remodulin is proven to diminish the rate of clinical deterioration of patients requiring transition from Flolan

Figure adapted with permission from Rubenfire M, et al. Chest. 2007.

93% of patients (13 of 14) successfully transitioned from epoprostenol IV to SC Remodulin1,2

Transitioning from Flolan to IV Remodulin3

  • In a 12-week, multicenter, open-label, investigator-initiated trial, 31 patients receiving optimal doses of conventional IV PAH therapies, as well as a stable dose of Flolan for ≥1 month were transitioned to IV Remodulin
  • 6MWD was maintained in patients changing from Flolan to IV Remodulin (438 m vs 439 m, respectively)
  • Borg dyspnea scores: no significant change

Transition from Flolan protocol

Transition from Flolan to Remodulin is accomplished by initiating and increasing the infusion of Remodulin (at a recommended dose of 10% of the current Flolan dose). The Remodulin dose should be increased as the Flolan dose is simultaneously decreased.1

Monitor your patients in a hospital to measure their response to Remodulin, including observing their vital signs, potential adverse reactions, and disease progression symptoms.1

6MWD=6-minute walk distance; IV=intravenous; PAH=pulmonary arterial hypertension; SC=subcutaneous.

Resources are available to help support you and your patients

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

References: 1. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018. 2. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007;132(3):757-763. 3. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586-1589.